Boltz, an AI biopharma startup, raised $110 million in a Series A less than a year after launching from stealth with $28 million. The financing underscores continued capital flow toward machine-learning-driven life-science platforms intended to compress discovery cycles. While details on specific therapeutic targets or productization milestones were not fully disclosed in the report, the funding size signals investor confidence in Boltz’s ability to turn model outputs into usable biology workflows. The round also suggests founders are moving quickly from concept toward operational scale. For biotech teams evaluating partners, Boltz’s raise is a reminder that AI-native discovery groups are competing aggressively for compute, data access, and industry integration timeframes.
Get the Daily Brief